BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...and gene-editing systems inside target cells (see “Strong-arming Drug Delivery” ). TransThera raises series C Nanjing TransThera Biosciences Co. Ltd....
...Eaton, Staff Writer Taletrectinib (AB-106, DS-6051, DS-6051b) AnHeart Therapeutics Inc. Daiichi Pharmaceutical Co. Ltd. JW Therapeutics (Shanghai) Co. Ltd. Eureka Therapeutics Nanjing TransThera Biosciences Co. Ltd. Cullinan...
BioCentury | Oct 17, 2016
Financial News

TransThera completes venture financing

...Nanjing TransThera Biosciences Co. Ltd., Nanjing, China Business: Cancer, Cardiovascular Date completed: 2016-10-13 Type: Venture financing...
BioCentury | Oct 13, 2016
Financial News

TransThera raises $10M in series A

...Nanjing TransThera Biosciences Co. Ltd. (Nanjing, China) said it raised about $10 million in a series...
...participated. The company said it will develop new chemical entities for cancer and cardiovascular disease. TransThera...
Items per page:
1 - 3 of 3
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...and gene-editing systems inside target cells (see “Strong-arming Drug Delivery” ). TransThera raises series C Nanjing TransThera Biosciences Co. Ltd....
...Eaton, Staff Writer Taletrectinib (AB-106, DS-6051, DS-6051b) AnHeart Therapeutics Inc. Daiichi Pharmaceutical Co. Ltd. JW Therapeutics (Shanghai) Co. Ltd. Eureka Therapeutics Nanjing TransThera Biosciences Co. Ltd. Cullinan...
BioCentury | Oct 17, 2016
Financial News

TransThera completes venture financing

...Nanjing TransThera Biosciences Co. Ltd., Nanjing, China Business: Cancer, Cardiovascular Date completed: 2016-10-13 Type: Venture financing...
BioCentury | Oct 13, 2016
Financial News

TransThera raises $10M in series A

...Nanjing TransThera Biosciences Co. Ltd. (Nanjing, China) said it raised about $10 million in a series...
...participated. The company said it will develop new chemical entities for cancer and cardiovascular disease. TransThera...
Items per page:
1 - 3 of 3